MAPS is granted Innovation Passport in United Kingdom for MDMA as an adjunct to therapy for PTSD

MAPS announced that "The Innovative Licensing and Access Pathway (ILAP) Innovation Passport has been granted to MDMA as an adjunct to therapy for posttraumatic stress disorder (PTSD) in the United Kingdom (UK). The ILAP designation, authorized by a steering group of representatives from Medicines and Healthcare products Regulatory Agency (MHRA), National Health Services of England and Scotland, National Institute for Health and Care Excellence, Scottish Medicines Consortium, and representatives from the ILAP Patient and Public Reference Group, acknowledges that this treatment may have unique potential as a safe and effective treatment for PTSD, a widespread and devastating mental health condition with few successful treatment options. The Innovation Passport does not reduce the burden of demonstrating that a treatment may be safe and effective, but does provide research organizers with expert advice, patient input, and collaboration throughout the clinical trial design and development process through a product-specific Target Development Profile." 

Two others psychedelics have also been granted the UK's fast-track ILAP - Small Pharma's use of a DMT-based formulation for depression and Eleusis's psilocybin-derivative also for depression.

For more psychedelic news and research, visit the psychedelic health professional network homepage.